Inspire Corporate Bond ETF IBD
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -4.01%
- 1 year
- -3.49%
- Open
- 23.22
- Prev close
- 23.15
- Mkt cap
- 481.43M
- Vol
- 110.51K
- Avg vol
- 101.23K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 23.20
- High
- 23.36
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 23.72
- 200-d avg
- 23.63
News
1 week ago investors.com
How Did This Low-Growth Stock Sneak Into IBD Growth Screens?
Rather than impressing with growth, Cincinnati, Ohio-based Cintas wins on scale and a dependable business.
1 week ago youtube.com
Meta's $1,000 Bull Case: How Muse AI Changes The Valuation Game | IBD
Meta's rollout of its new Muse AI agent marks a pivotal moment for the tech giant. But investors are questioning whether the model will be a lucrative revenue driver or an expensive defensive move.
2 weeks ago gurufocus.com
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
SKYRIZIÂ (risankizumab) and RINVOQÂ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2
2 weeks ago prnewswire.com
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs Latest long-term and real-world data with SKYRIZI® (risankizumab) and…
2 weeks ago zacks.com
Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?
Launched on 07/10/2017, the Inspire Corporate Bond ETF (IBD) is a smart beta exchange traded fund offering broad exposure to the Investment Grade Corporate Bond ETFs category of the market.
2 weeks ago gurufocus.com
Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 2026
Celltrion to Present New Analyses of ZYMFENTRAÂ (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 2026PR NewswireJERSEY CITY, N.J., Oct. 11, 2
2 weeks ago gurufocus.com
New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
New SKYRIZIÂ (risankizumab-rzaa) and RINVOQÂ (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel DiseasePR NewswireNOR
3 weeks ago gurufocus.com
New Opportunities for Global Cooperation: Kexing Biopharm Shines at CPHI Milan 2026
New Opportunities for Global Cooperation: Kexing Biopharm Shines at CPHI Milan 2026PR NewswireMILAN, Oct. 10, 2026MILAN, Oct. 10, 2026 /PRNewswire/ -- From Octo
3 weeks ago seekingalpha.com
Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential
Spyre Therapeutics maintains a 'Strong Buy' rating, driven by promising IBD pipeline progress and robust cash reserves. SYRE's three monotherapy candidates—SPY001, SPY002, SPY003—show potential…
1 month ago investors.com
AI-Fueled Precision Oncology Firm Guardant Health Is In Focus. Here's Why.
Earning a spot on the IBD Leaderboard and IBD 50, Guardant Health stress tests a breakout.
1 month ago globenewswire.com
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p
2 months ago prnewswire.com
Inspire Corporate Bond Fund (IBD) Receives 5-star Overall Morningstar Rating™ Among 155 Corporate Bond Funds
BOISE, Idaho, Aug. 25, 2026 /PRNewswire/ -- Inspire Investing is pleased to announce that the Inspire Corporate Bond ETF (NYSE: IBD) has been awarded a 5-star Overall Morningstar Rating™ for the…
2 months ago zacks.com
Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?
SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in SKYLIGHT.
2 months ago zacks.com
Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?
Launched on 07/10/2017, the Inspire Corporate Bond ETF (IBD) is a smart beta exchange traded fund offering broad exposure to the Investment Grade Corporate Bond ETFs category of the market.
3 months ago youtube.com
Beyond The Megacaps: What To Watch In Eli Lilly, Sandisk, SpaceX Earnings | IBD
IBD's Alexis Garcia and Ed Carson preview key upcoming earnings reports from Eli Lilly, Sandisk and SpaceX. Check out our daily newsletter!
3 months ago benzinga.com
Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2
Oppenheimer on Thursday initiated coverage of Palisade Bio Inc. (NASDAQ:PALI) , saying the stock offers investors an attractive way to gain exposure to the fast-growing inflammatory bowel disease…
3 months ago youtube.com
Why The Anthropic-Pentagon Clash Matters For The Entire AI Tech Stack | IBD
Is the federal government's clash with Anthropic a warning sign for the entire artificial intelligence ecosystem? Tech strategist and Georgetown adjunct law professor Emily Benson breaks down the…
4 months ago 247wallst.com
One AI Cooling Stock Is 10% Off Highs. Why IBD Says the Setup ‘Doesn't Get Much Better'
The AI buildout's real bottleneck is the steel, copper, and chilled water surrounding the GPUs.
4 months ago zacks.com
Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?
A smart beta exchange traded fund, the Inspire Corporate Bond ETF (IBD) debuted on 07/10/2017, and offers broad exposure to the Investment Grade Corporate Bond ETFs category of the market.
5 months ago prnewswire.com
AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
AbbVie presents 18 abstracts in Crohn's disease and ulcerative colitis Breadth of data from real-world evidence and clinical trials reinforce risankizumab and upadacitinib efficacy, safety profile,…